SCHEMBL3108685

SCHEMBL3108685

CCCc1c(C(=O)NC2CC2)nnn1-c1ccc(NC(N)=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.47
▸ POLB P06746 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.39
▸ MAPT P10636 5/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ RIPK1 Q13546 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ GABRA5 P31644 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3099742 0.91 ROCK1 (0.48) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3108746 0.90 ROCK1 (0.46) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3107465 0.90 ROCK1 (0.47) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3115899 0.89 ROCK1 (0.47) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3111198 0.89 ROCK1 (0.49) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3106601 0.89 ROCK1 (0.47) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3109629 0.89 ROCK1 (0.47) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3107222 0.88 ROCK1 (0.45) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3107151 0.88 ROCK1 (0.46) ROCK1POLBRXFP1MAPTALDH1A1
SCHEMBL3115126 0.88 ROCK1 (0.46) ROCK1POLBRXFP1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 ROCK1 1430/4885POLB 3558/4885RXFP1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback